Life Sciences Drug DevelopmentBurlington, MA
The Company’s lead product is ARQ 197, an orally administered inhibitor of the c-Met receptor tyrosine kinase. ARQ 197 is currently being evaluated in the clinic as monotherapy and in combination therapy. ArQule has licensed commercial rights to ARQ 197 for human cancer indications to Daiichi Sankyo Co., Ltd. in the U.S., Europe, South America and the rest of the world, excluding Japan and certain other Asian countries, where commercial rights have been licensed to Kyowa Hakko Kirin Co., Ltd. ArQule’s product pipeline offers the potential for multiple therapeutic candidates based on diverse biological targets, mechanisms of action and chemistry. The pipeline includes of inhibitors of the Eg5 kinesin spindle protein and the BRAF kinase, as well as activators of the cell’s DNA damage response mechanism mediated by the E2F-1 transcription factor. The Company’s drug discovery efforts are focused primarily on the ArQule Kinase Inhibitor Platform (“AKIP™”), employed to generate a new class of compounds designed to inhibit a variety of kinases potently, selectively and without competing with adenosine triphosphate.